• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
COVID-19
Sunum

Sunum
Open Access
Kaynak :
Piri Sunum Koleksiyonu
Yazar(lar) :
Mustafa TAYAR
Yıl :
2020
COVID-19 CORONAVIRUS ( COVID- 19) ile mücadele programı Prof.Dr.Mustafa TAYAR İşyerinizi COVID-19a hazır hale getirme SIMULATION EXERCISE NOVEL CORONAVIRUS ( COVID Tuesday, October 27, 2020 SIMULATION EXERCISE NOVEL CORONAVIRUS ( COVID- 19) page 4 Coronavirüsten korunma yolları Tuesday, October 27, 2020 SIMULATION EXERCISE NOVEL CORONAVIRUS ( COVID- 19) page 5 Okullar için önemli hijyen noktaları Tuesday, October 27, 2020 SIMULATION EXERCISE NOVEL CORONAVIRUS ( COVID- 19) page COVID-19
Yayıncı Web Sitesi
Kaydet Alıntıla
CORONAVIRUS (COVID-19) ile mücadele programı Prof.Dr.Mustafa TAYAR İşyerinizi COVID-19a hazır hale getirme SIMULATION EXERCISE NOVEL CORONAVIRUS (COVID-19) page 2 Çalışma alanınız,virüslere ve salgınlara karşı hazırlıklı mı? Tuesday, October 27, 2020 Öğrenciler, çalışanlar ve misafirleriniz coronavirüs ile karşı karşıya kalma durumlarında güvenli bir çalışma ortamının sağlanmasına ihtiyaç duyarlar SIMULATION EXERCISE NOVEL CORONAVIRUS (COVID-19) page 3 Coronavirüs nedir? Tuesday, October 27, 2020 SIMULATION EXERCISE NOVEL CORONAVIRUS (COVID-19) page 4 Coronavirüsten korunma yolları Tuesday, October 27, 2020 SIMULATION EXERCISE NOVEL CORONAVIRUS (COVID-19) page 5 Okullar için önemli hijyen noktaları Tuesday, October 27, 2020 SIMULATION EXERCISE NOVEL CORONAVIRUS (COVID-19) page 6 Yemekhane
Anahtar Kelimeler : COVID-19
Sunum Formatı : pptx
Sunum Sayfa Sayısı : 27
Sınıflandırma :
Biyotıp %100
2
COVID-19-associated encephalopathy: Neurological manifestation of COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Radiology Case Reports
Yazar(lar) :
Safaa Saeed Al Mazrouei , MBBS , Ghufran Aref Saeed , MBBS , Abeer Ahmed Al Helali , MBBS , Manzoor Ahmed , MBBS
Yıl :
2020
COVID-19-associated encephalopathy: Neurological manifestation of COVID-19 Coronavirus disease 2019 ( COVID- 19) is a viral disease, also known as severe acute respiratory syndrome coronavirus 2, was first reported in Wuhan, China COVID- 19-associated neurological manifestations have not been widely reported. In this report, we describe a case of encephalopathy in a patient with COVID- 19 infection. Covid-19
Yayıncı Web Sitesi
Kaydet Alıntıla
Coronavirus disease 2019 (COVID-19) is a viral disease, also known as severe acute respiratory syndrome coronavirus 2, was first reported in Wuhan, China, December 2019. Respiratory manifestations from the induced acute lung injury were the most common reported findings. Few cases showed extrapulmonary manifestations. COVID-19-associated neurological manifestations have not been widely reported. In this report, we describe a case of encephalopathy in a patient with COVID-19 infection.
Anahtar Kelimeler : Covid-19, coronavirus, RT-PCR, reverse transcription polymerase chain reaction, central nervous system, Encephalopathy
ISSN: 1930-0433
Cilt: 15
Sayı: 9
Sayfa: 1646 - 1649
Sınıflandırma :
3
COVID-19 solution
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
International Journal of Preventive Medicine
Yazar(lar) :
Roberto Menicagli , Mario Limodio
Yıl :
2020
COVID-19 solution Some CoVs have recently entered humans from infected animals and lastly we have SARS COVID- 19, (CoV), which causes severe acute, often fatal respiratory sars covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Coronaviruses (CoV) are RNA viruses that cause endemic infections in various species of mammals and avian birds. There are seven known human CoVs, each of which causes respiratory diseases: together account for about one third of common colds. Some CoVs have recently entered humans from infected animals and lastly we have SARS COVID-19, (CoV), which causes severe acute, often fatal respiratory syndromes. The prevalence of CoV, the easy zoonotic transmission and the potential to cause serious respiratory diseases, lead to urgent research to discover the mechanisms of CoV infection. Our study has identified a possible way to eliminate the danger of this virus by analyzing the structures by which it enters the host cell. This study indicates that the neuroaminidase interrupts the infection.
DOI : 10.4103/ijpvm.IJPVM_227_20
Anahtar Kelimeler : neuroaminidase, sars covid-19, sialic acid
Cilt: 11
Sayı: 1
Sayfa: 73 - 73
Sınıflandırma :
Viroloji %95
4
Why COVID-19?
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Advanced Journal of Emergency Medicine
Yazar(lar) :
Elnaz Vahidi , Mohammad Jalili
Yıl :
2020
Why COVID-19? Covid- 19 has been estimated to have a case fatality rate of around 3%. In late December 2019, an outbreak of COVID- 19 was reported from Wuhan city, China. Today COVID- 19 has affected more than 212 countries and has made billions of people to be quarantined in their houses.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
COVID-19 is a highly contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), an enveloped positive stranded RNA virus and the third member of the family Coronaviridae which has emerged as a zoonotic infection. The predecessor of this new pathogen caused the Severe Acute Respiratory Syndrome (SARS) in 2003 and the Middle East Respiratory Syndrome (MERS) in 2012. Although corona viruses have been known since 1960’s, their familiar species were human pathogens and caused common cold and seasonal flu. SARS-CoV-2 is easily transmitted via respiratory secretions of an infected person, with a reproductive number (the average number of cases to which a single infected person will transmit the virus) of 1.4-2.5. Covid-19 has been estimated to have a case fatality rate of around 3%. As of today, asymptomatic transmission is assumed to be possible during the incubation period, which usually ranges from 2-14 days. The source of infection, animal host, and reservoir are currently unknown. In late December 2019, an outbreak of COVID-19 was reported from Wuhan city, China. The disease soon spread outside China borders and became rapidly prevalent all around the world. The pandemic announcement was officially made by World Health Organization (WHO) on 11 March 2020. Today COVID-19 has affected more than 212 countries and has made billions of people to be quarantined in their houses. Up to now, almost 1500000 confirmed cases of COVID-19 have been reported globally and the death toll has been declared to be 86000. In Iran, we are also facing this unprecedented global public health emergency, with about 65000 confirmed cases and 3993 deaths. This pandemic is beyond an expanding contagious disease and has influenced different features of life. Its enormous social, political, and specifically economic impacts all around the world are undeniable. In low- and middle-income countries this can potentially lead to a huge spike in poverty and collapse. Many vulnerable families have lost their income and access to the essential needs. Education systems have collapsed in many regions. The long-term effect of this global crisis has reduced economic growth even in developed countries. Economic effects of COVID-19 are estimated with dramatic variations. Orlik et al in Bloomberg hypothesized this cost to be $2.7 trillion. The political consequences are even harder to predict but quite significant and devastating, like the heated discussion, criticism and accusation flowing between the leaders of different countries. Since the pandemic is not yet over, the global influence will carry on to happen and make situation even more complicated. While the outbreak is evolving rapidly, health care systems across the world are actively fighting against the new virus. They have encountered many new challenges. Public health measures (such as active case finding, prompt isolation of cases and contacts tracing) to contain the spread of the disease in the society as well as provision of care for the unpredictably high number of people who are infected with the virus have stretched the healthcare system beyond its capacity. At the same time, protecting health care providers’ safety, which often requires provision of sufficient supplies of personal protective equipment, has definitely challenged the system. Societal demand for discovery of a definitive treatment and vaccine has also added to the complexity of the situation that the health care systems are facing. Studies about COVID-19 are increasingly being performed and published; many of them have not yet been fully reviewed and criticized by the academic community. Practitioners often find it difficult to find, appraise and apply the information they need amid the turbulence of their clinical practice. Furthermore, there are still many questions to be answered. The most efficient method for personal protection, methods of viral transmission, most accurate diagnostic approaches, and effective treatment options are yet to be determined. This special issue of the Advanced Journal of Emergency Medicine plans to specifically focus on COVID-19 by gathering the relevant scientific information available. We hope that by publishing high quality papers, this journal can provide its readers with further required information. Appropriate management of patients suffering COVID-19 as well as controlling this pandemic are our ultimate aspirations. We encourage further researches in this field by all scientists and physicians all across the world to be able to eradicate COVID-19 as soon as possible.
DOI : 10.22114/ajem.v0i0.402
ISSN: 2588-400X
Sınıflandırma :
Viroloji %77
5
Fighting COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Brazilian Journal of Biology
Yazar(lar) :
D. M. O. Campos , C. B. S. Oliveira , J. M. A. Andrade , J. I. N. Oliveira
Fighting COVID-19 Abstract The current COVID- 19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Abstract The current COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and severe forms of respiratory infection. The lack of vaccines and antivirals prevents clinical strategies against the disease, creating an emerging need for the development of safe and effective treatments. Strategies for vaccine development include complete vaccines against viruses, subunits, and nucleic acids, but are still in their early stages. Studies carried out to date on possible SARS-CoV2 drug targets highlight glycoprotein S, Mpro (main protease or protease type 3C), and a member of the transmembrane serine protease II families (TMPRSS2). However, due to the pandemic state, priority is given to marketed drugs. These include chloroquine (CQ), hydroxychloroquine (HCQ), nitazoxanide, remdesivir, Lopinavir/ritonavir (LPV / r), in addition to treatment with convalescent plasma. But, therapeutic specific effects against SARS-CoV2 have not yet been verified. Most of the information obtained about treatment is based on preliminary and limited studies. We conclude that, at this time of emergency, the search for new therapies is more urgent due to the need to save lives. Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2.
DOI : 10.1590/1519-6984.238155
Anahtar Kelimeler : virology, sars-cov2, covid-19, infectious diseases
Sınıflandırma :
Biyotıp %100
Viroloji %99
6
Asymptomatic COVID-19 Infection Management: The Key to Stop COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Clinical and Experimental Investigations
Yazar(lar) :
Rachid Ait Addi , Abdelhafid Benksim , Mohamed Amine , Mohamed Cherkaoui
Yıl :
2020
Asymptomatic COVID-19 Infection Management: The Key to Stop COVID-19 The COVID- 19 disease, emerged in December 2019, has spread rapidly, with new cases confirmed in multiple countries. portion of the population to virus and increase the late diagnosis and thereafter enhance COVID- 19 mortality. Thereafter, it is fundamental to review our COVID- 19 screening approach and enlarge COVID- 19 testing to the general population by using rapid testing appliances COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The COVID-19 disease, emerged in December 2019, has spread rapidly, with new cases confirmed in multiple countries. Many efforts to contain the virus are ongoing, such as containment, individual measures of protection, the authorization of use of some drugs as chloquorine in some countries. Also, it has been known that symptomatic and asymptomatic people whom are infected by COVID-19 have the same contagiousness which expose a far greater portion of the population to virus and increase the late diagnosis and thereafter enhance COVID-19 mortality. Thereafter, it is fundamental to review our COVID-19 screening approach and enlarge COVID-19 testing to the general population by using rapid testing appliances such as rapid SARS-CoV-2 IgG-IgM combined antibody since another appliance more efficient will be performed.
DOI : 10.5799/jcei/7866
Anahtar Kelimeler : COVID-19, pandemic, screening, diagnosis
Cilt: 11
Sayı: 3
Sayfa:
Sınıflandırma :
7
COVID-19: Immunopathogenesis
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi
Yazar(lar) :
Deniz MAVİ , Ahmet Çağkan İNKAYA
Yıl :
2020
COVID-19: Immunopathogenesis Coronavirus- 19 disease ( COVID- 19) first described in Wuhan, China at the end of 2019. respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks may help to elucidate the pathogenesis of COVID - 19.
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Coronavirus-19 disease (COVID-19) first described in Wuhan, China at the end of 2019. It spread rapidly all over the world and claimed the lives of over 300,000 people. There is no known effective vaccine and treatment yet. It is impossible to develop vaccines and specific treatment without understanding the pathogenesis of the disease. Experience from severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks may help to elucidate the pathogenesis of COVID-19. Nevertheless, many issues remained obscure regarding the pathogenesis of SARS-CoV-2. Exaggerated immune response leads to respiratory failure and even complications which may culminate in death. Cytokines storm, the complement system, endothelial damage, coagulation cascade, cellular and humoral immunity all play an important role in immune pathogenesis and inflammation. In this review, the relationship between the immune response/host characteristics of SARS-CoV-2 and the severity of the disease, antibody responses, and immune pathogenesis, possible causes of hypercoagulation will be discussed and it’s aimed to provide perspective on the development of effective vaccines and specific treatment.
DOI : 10.5578/flora.69606
Anahtar Kelimeler : sars-cov, sars-cov-2, immunopathogenesis, cytokine storm
ISSN: 1300-932X
Cilt: 25
Sayı: 2
Sayfa: 121 - 131
Sınıflandırma :
Viroloji %74
8
COVID 19: Neuromuscular manifestations
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Annals of Indian Academy of Neurology
Yazar(lar) :
Rajesh Benny , Satish V Khadilkar
Yıl :
2020
COVID 19: Neuromuscular manifestations COVID- 19 pandemic is ongoing and information on the neurological aspects of this viral infection is being gathered. This manuscript studies the available information on the neuromuscular manifestations of COVID- 19. covid-19 neurological manifestations covid-19 neuromuscular manifestations
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
COVID-19 pandemic is ongoing and information on the neurological aspects of this viral infection is being gathered. Neuromuscular manifestations have been reported uncommonly in these early stages of the analysis. This manuscript studies the available information on the neuromuscular manifestations of COVID-19.
DOI : 10.4103/aian.AIAN_309_20
Anahtar Kelimeler : covid-19 neurological manifestations, covid-19 neuromuscular manifestations, guillain barre syndrome, myositis
Cilt: 23
Sayı: 7
Sayfa: 40 - 42
Sınıflandırma :
Viroloji %27
9
COVID-19 and hypertension
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of the Renin-Angiotensin-Aldosterone System
Yazar(lar) :
Spoorthy Kulkarni , Bernadette L. Jenner , Ian Wilkinson
Yıl :
2020
COVID-19 and hypertension
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.1177/1470320320927851
Cilt: 21
Sınıflandırma :
10
Cannabinoids and COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Medical Cannabis and Cannabinoids
Yazar(lar) :
Myriam El Biali , Barbara Broers , Marie Besson , Jules Demeules
Yıl :
2020
Cannabinoids and COVID-19 involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Since the endocannabinoid system is involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. Some data suggest that the immunomodulatory effect of cannabinoids may affect the course and severity of SARS-CoV-2 infection. Given the large number of cannabinoids consumers in the community, this commentary presents the current knowledge on the potential impact of cannabinoids and endocannabinoids on bacterial and viral infection courses namely SARS-CoV-2 disease. Practical recommendations, which can be drawn from the literature, are given.
DOI : 10.1159/000510799
Anahtar Kelimeler : sars-cov-2, covid-19, immunity, cannabinoids, endocannabinoid system
ISSN: 2504-3889
Sayfa: 1 - 5
Sınıflandırma :
11
Tobacco and COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Eurasian Journal of Pulmonology
Yazar(lar) :
Ozlem Sonmez , Zeynep Atam Taşdemir , H Volkan Kara , Sule Akçay
Yıl :
2020
Tobacco and COVID-19 Similar data have been approved found for coronavirus disease-2019 ( COVID- 19) pandemic. adverse effects of tobacco and tobacco products and to raise awareness among the public and to make efforts to smoking on every opportunity during the COVID - 19 pandemic. covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Tobacco and its products are the well-known causes of premature deaths associated with cancer, cardiovascular disease, and chronic obstructive pulmonary disease, as well as they constitute a significant risk factor that increases the tendency to respiratory system infection and other systemic infections. Active tobacco use and passive smoking increase the risk of infection. Both increase peribronchial and alveolar inflammation and fibrosis and mucosal permeability, cause inadequate mucociliary cleaning, damage to the respiratory tract epithelium resulting in fibrosis, and they adversely affect cellular and humoral immunity. Smoking has been known to increase the risk for viral infections and influenza. Similar data have been approved found for coronavirus disease-2019 (COVID-19) pandemic. Smoking is reported to be associated with the frequency of the disease and its severity of the clinical course. Severe acute respiratory syndrome-coronavirus-2 penetrates the cell using the angiotensin-converting enzyme 2 receptors. Such receptor proteins had been shown to increase in smoker individuals. Also, smoking facilitates penetration of the virus into the cell. The frequency of smoking and the rates of admission to intensive care, mechanical ventilation, and mortality have been also found to be higher was higher in severe cases. The risk for disease progression was found to be 14-fold higher in smokers. Further, the World Health Organization emphasized similar negative effects of hookah and new tobacco products such as electronic cigarettes and heated tobacco products. It is vital to underline the adverse effects of tobacco and tobacco products and to raise awareness among the public and to make efforts to smoking on every opportunity during the COVID-19 pandemic. Public awareness campaigns during the pandemic must always accompanied by the methods and strategies to avoid active and passive smoking.
DOI : 10.4103/ejop.ejop_52_20
Anahtar Kelimeler : covid-19, sars-cov-2, smoking, tobacco use
Cilt: 22
Sayı: 4
Sayfa: 12 - 15
Sınıflandırma :
12
COVID-19: a review
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Monaldi Archives for Chest Disease
Yazar(lar) :
Irappa Madabhavi , Malay Sarkar , Nagaveni Kadakol
Yıl :
2020
COVID-19: a review The enduring epidemic outbreak which started in Wuhan city of China, in December 2019 caused by the 2019 novel coronavirus ( COVID- 19) or the severe acute A highly virulent and pathogenic COVID- 19 viral infection with incubation period ranging from two to fourteen days, transmitted by breathing of infected Approximately 1,016,128 reported cases, 211,615 recovered cases and 53,069 deaths of COVID-2019 have been reported to date (April 2, 2020). COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The enduring epidemic outbreak which started in Wuhan city of China, in December 2019 caused by the 2019 novel coronavirus (COVID- 19) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created a dangerous and deadly Public Health disaster of International apprehension, with cases confirmed in several countries. This novel community health trouble is frightening the universe with clinical, psychological, emotional, collapse of health system and economical slowdown in each and every part of the world infecting nearly 200 countries. A highly virulent and pathogenic COVID-19 viral infection with incubation period ranging from two to fourteen days, transmitted by breathing of infected droplets or contact with infected droplets, belongs to the genus Coronavirus with its high mutation rate in the Coronaviridae. The likely probable primary reservoir could be bats, because genomic analysis discovered that SARSCoV-2 is phylogenetically interrelated to SARS-like bat viruses. The transitional resource of origin and transfer to humans is not known, however, the rapidly developing pandemic has confirmed human to human transfer. Approximately 1,016,128 reported cases, 211,615 recovered cases and 53,069 deaths of COVID-2019 have been reported to date (April 2, 2020). The symptoms vary from asymptomatic, low grade pyrexia, dry cough, sore throat, breathlessness, tiredness, body aches, fatigue, myalgia, nausea, vomiting, diarrhea, to severe consolidation and pneumonia, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction leading to death with case fatality rate ranging from 2 to 3%.
DOI : 10.4081/monaldi.2020.1298
Anahtar Kelimeler : Coronavirus, COVID-19, outbreak, infection, pneumonia
Cilt: 90
Sayı: 2
Sınıflandırma :
13
Pathogenesis of COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak 1:
Directory of Open Access Journals (DOAJ)
Kaynak 2:
Directory of Open Access Journals (DOAJ)
Dergi:
Eurasian Journal of Pulmonology
Yazar(lar) :
Evrim Eylem Akpinar
Yıl :
2020
Pathogenesis of COVID-19 The coronavirus disease 2019 ( COVID- 19) is a very contagious infectious disease which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV The aim of this report is to review the immunopathogenesis of COVID- 19 in the light of current literature. covid-19
Piri Tam Metin Bulucu
Kaydet Alıntıla
The coronavirus disease 2019 (COVID-19) is a very contagious infectious disease which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus is first identified in Wuhan city of China in December 2019 and in a short time dispersed to rest of the World. Animal to human transmission of the virus happened by eating of an infected animal and then the virus is transmitted to healthy persons by close contact. Coronaviruses attach and enter to the host cells by means of the spikes on the cell membrane. The type 2 pneumocytes are the primary target of the virus. The aim of this report is to review the immunopathogenesis of COVID-19 in the light of current literature.
DOI : 10.4103/ejop.ejop_54_20
Anahtar Kelimeler : coronavirus, covid-19, pathogenesis
Cilt: 22
Sayı: 4
Sayfa: 8 - 11
Sınıflandırma :
Viroloji %88
14
COVID-19: Apocalypse Now?
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Cellular and Molecular Anesthesia
Yazar(lar) :
Ali Dabbagh
Yıl :
2020
COVID-19: Apocalypse Now?
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.22037/jcma.v5i1.29845
Cilt: 5
Sayı: 1
Sayfa: 1 - 2
Sınıflandırma :
15
Covid-19 and Neurology
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Türk Nöroloji Dergisi
Yazar(lar) :
Şerefnur Öztürk
Yıl :
2020
Covid-19 and Neurology Coronavirus disease- 19 ( COVID- 19) pandemic is a new and important burden for the neurological area. mechanisms of neurological involvement of the disease may be explained more efficiently by neurologists who are included within the multidisciplinary COVID - 19 teams. covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Neurological diseases are the most common and important health burden over the world. Coronavirus disease-19 (COVID-19) pandemic is a new and important burden for the neurological area. Information related to the neurological involvement of Severe Acute Respiratory syndrome-Coronavirus-2 infection has been increased during the last several months. Frequency and mechanisms of neurological involvement of the disease may be explained more efficiently by neurologists who are included within the multidisciplinary COVID-19 teams. Other very important point is possibility of failure of follow up and treatment of chronic neurological disorders which needed frequent and regular control and also quick action for the acute treatment. The regulations are extremely important for the neurologists to perform their responsibilities with considering all these requirements.
DOI : 10.4274/tnd.2020.73384
Anahtar Kelimeler : covid-19, neurology, turkey
Cilt: 26
Sayı: 2
Sayfa: 109 - 111
Sınıflandırma :
16
COVID-19 and epilepsy
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Annals of Indian Academy of Neurology
Yazar(lar) :
Sora Yasri , Viroj Wiwanikit
Yıl :
2020
COVID-19 and epilepsy
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.4103/aian.AIAN_254_20
Cilt: 23
Sayı: 7
Sayfa: 43 - 43
Sınıflandırma :
17
Coping with COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Lumbini Medical College
Yazar(lar) :
Bhagavat Nepal , Prof
Yıl :
2020
Coping with COVID-19 Antivirals, specifically Remdesivir has been a strong candidate for the treatment of COVID- 19. However, it has yet to receive universal acceptance for the treatment of COVID- 19. These findings suggest the hypothesis that anti-malarial drugs have efficacy in the treatment of COVID- 19. COVID 19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Severe acute respiratory syndrome corona virus (SARS-CoV-2) virus made its first appearance in Wuhan, China in December 2019. It has since spread like a wild fire across the globe with over five million corona virus disease (COVID-19) confirmed cases and almost three hundred fifty thousand deaths at the time of writing this article. This could however be only the tip of the iceberg considering the contagious nature of the SARS-CoV-2 virus and the rate at which it is spreading across the globe. China did well to contain the virus with strict lockdown measures, sealing the affected areas, active case finding, tracing, tracking and treating the COVID-19 cases at an astonishing speed. In the absence of specific treatment available as yet, treatment consists of mainly symptomatic management with some experimental medications. Antivirals, specifically Remdesivir has been a strong candidate for the treatment of COVID-19. However, it has yet to receive universal acceptance for the treatment of COVID-19. Chloroquine and Hydroxychloroquine seem to be effective in limiting the replication of SARS-CoV-2 virus in vitro. COVID-19 is highly pandemic in countries where malaria is least prevalent and least pandemic in countries where malaria is highly prevalent. These findings suggest the hypothesis that anti-malarial drugs have efficacy in the treatment of COVID-19.
DOI : 10.22502/jlmc.v8i1.355
Anahtar Kelimeler : COVID 19
Cilt: 8
Sayı: 1
Sınıflandırma :
18
Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Vaccines
Yazar(lar) :
Jiahao Wang , Rize Jing , Xiaozhen Lai , Haijun Zhang , Yun Lyu , Maria Deloria Knoll , Hai Fang
Yıl :
2020
Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China Background: Faced with the coronavirus disease 2019 ( COVID- 19) pandemic, the development of COVID- 19 vaccines has been progressing at an unprecedented of vaccines against COVID- 19 during the pandemic. - 19 vaccination or valuing doctor’s recommendations could increase the probability of accepting COVID- 19 vaccination as soon as possible, while having COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Background: Faced with the coronavirus disease 2019 (COVID-19) pandemic, the development of COVID-19 vaccines has been progressing at an unprecedented rate. This study aimed to evaluate the acceptance of COVID-19 vaccination in China and give suggestions for vaccination strategies and immunization programs accordingly. Methods: In March 2020, an anonymous cross-sectional survey was conducted online among Chinese adults. The questionnaire collected socio-demographic characteristics, risk perception, the impact of COVID-19, attitudes, acceptance and attribute preferences of vaccines against COVID-19 during the pandemic. Multivariate logistic regression was performed to identify the influencing factors of vaccination acceptance. Results: Of the 2058 participants surveyed, 1879 (91.3%) stated that they would accept COVID-19 vaccination after the vaccine becomes available, among whom 980 (52.2%) wanted to get vaccinated as soon as possible, while others (47.8%) would delay the vaccination until the vaccine’s safety was confirmed. Participants preferred a routine immunization schedule (49.4%) to emergency vaccination (9.0%) or either of them (41.6%). Logistic regression showed that being male, being married, perceiving a high risk of infection, being vaccinated against influenza in the past season, believing in the efficacy of COVID-19 vaccination or valuing doctor’s recommendations could increase the probability of accepting COVID-19 vaccination as soon as possible, while having confirmed or suspected cases in local areas, valuing vaccination convenience or vaccine price in decision-making could hinder participants from immediate vaccination. Conclusion: During the pandemic period, a strong demand for and high acceptance of COVID-19 vaccination has been shown among the Chinese population, while concerns about vaccine safety may hinder the promotion of vaccine uptake. To expand vaccination coverage, immunization programs should be designed to remove barriers in terms of vaccine price and vaccination convenience, and health education and communication from authoritative sources are important ways to alleviate public concerns about vaccine safety.
DOI : 10.3390/vaccines8030482
Anahtar Kelimeler : SARS-CoV-2, COVID-19, immunization, vaccine acceptance, vaccine preference
ISSN: 2076-393X
Cilt: 8
Sayı: 482
Sayfa: 482
Sınıflandırma :
19
Stand on the Same Side Against Covid – 19 Clinical Management of Covid-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Substantia
Yazar(lar) :
Lorenzo Corbetta , Leonardo M. Fabbri , Shiyue Li , Jing Li , Bin Cao , Jin Yang , Giancarlo Agnelli , Michela Giustozzi , Alberto Mantovani , Luigi Camporota , Semra Bilaçeroğlu , Adrian Rendon
Yıl :
2020
Stand on the Same Side Against Covid – 19 Clinical Management of Covid-19 Covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
This document is the direct transcription of a Webinar organized by Prof. L. Corbetta of the University of Florence on May 29th, 2020.
DOI : 10.13128/Substantia-1022
Anahtar Kelimeler : Covid-19, Clinical Management, LOTUS China Trial, Lopinavir, Ritonavir, Wuhan
ISSN: 2532-3997
Cilt: 4
Sayı: 1
Sınıflandırma :
20
COVID-19 and lung pathology
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Indian Journal of Pathology and Microbiology
Yazar(lar) :
Amita Jain
Yıl :
2020
COVID-19 and lung pathology
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.4103/IJPM.IJPM_280_20
Cilt: 63
Sayı: 2
Sayfa: 171 - 172
Sınıflandırma :
21
Hemophagocytic syndrome and COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Respiratory Medicine Case Reports
Yazar(lar) :
Ricardo Lima , Célio Cortinhas Filho , Carlos Martins Ferreira Filho , Mauricio Vaisman , Alexandre Cossenza , Caroline Pinto Rebello , Carolina de Andrade Leite , Danilo de Oliveira Tavares , Julia Falconiere Ramalho
Yıl :
2020
Hemophagocytic syndrome and COVID-19 The case of a woman hospitalized due to COVID- 19 is presented.
Yayıncı Web Sitesi
Kaydet Alıntıla
The case of a woman hospitalized due to COVID-19 is presented. The patient developed a severe macrophage activation syndrome diagnosed by bone marrow biopsy, which did not respond to immunoglobulin therapy.
ISSN: 2213-0071
Cilt: 31
Sayfa: 101162
Sınıflandırma :
Hematoloji %100
22
COVID-19: immunopathogenesis and Immunotherapeutics
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Signal Transduction and Targeted Therapy
Yazar(lar) :
Li Yang , Shasha Liu , Jinyan Liu , Zhixin Zhang , Xiaochun Wan , Bo Huang , Youhai Chen , Yi Zhang
Yıl :
2020
COVID-19: immunopathogenesis and Immunotherapeutics Abstract The recent novel coronavirus disease ( COVID- 19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a Therefore, mechanisms underlying immune abnormalities in patients with COVID- 19 must be elucidated to guide clinical management of the disease. strategies against COVID- 19.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Abstract The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected patients worldwide. The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations. SARS-CoV-2 not only activates antiviral immune responses, but can also cause uncontrolled inflammatory responses characterized by marked pro-inflammatory cytokine release in patients with severe COVID-19, leading to lymphopenia, lymphocyte dysfunction, and granulocyte and monocyte abnormalities. These SARS-CoV-2-induced immune abnormalities may lead to infections by microorganisms, septic shock, and severe multiple organ dysfunction. Therefore, mechanisms underlying immune abnormalities in patients with COVID-19 must be elucidated to guide clinical management of the disease. Moreover, rational management of the immune responses to SARS-CoV-2, which includes enhancing anti-viral immunity while inhibiting systemic inflammation, may be key to successful treatment. In this review, we discuss the immunopathology of COVID-19, its potential mechanisms, and clinical implications to aid the development of new therapeutic strategies against COVID-19.
DOI : 10.1038/s41392-020-00243-2
ISSN: 2059-3635
Cilt: 5
Sayı: 1
Sayfa: 1 - 8
Sınıflandırma :
Biyotıp %100
Viroloji %37
23
Nutrition, immunity and COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
BMJ Nutrition, Prevention & Health
Yazar(lar) :
Philip C Calder
Yıl :
2020
Nutrition, immunity and COVID-19 Gut dysbiosis is a feature of disease including many infectious diseases and has been described in COVID- 19. This is seen in cases of severe COVID- 19.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The immune system protects the host from pathogenic organisms (bacteria, viruses, fungi, parasites). To deal with this array of threats, the immune system has evolved to include a myriad of specialised cell types, communicating molecules and functional responses. The immune system is always active, carrying out surveillance, but its activity is enhanced if an individual becomes infected. This heightened activity is accompanied by an increased rate of metabolism, requiring energy sources, substrates for biosynthesis and regulatory molecules, which are all ultimately derived from the diet. A number of vitamins (A, B6, B12, folate, C, D and E) and trace elements (zinc, copper, selenium, iron) have been demonstrated to have key roles in supporting the human immune system and reducing risk of infections. Other essential nutrients including other vitamins and trace elements, amino acids and fatty acids are also important. Each of the nutrients named above has roles in supporting antibacterial and antiviral defence, but zinc and selenium seem to be particularly important for the latter. It would seem prudent for individuals to consume sufficient amounts of essential nutrients to support their immune system to help them deal with pathogens should they become infected. The gut microbiota plays a role in educating and regulating the immune system. Gut dysbiosis is a feature of disease including many infectious diseases and has been described in COVID-19. Dietary approaches to achieve a healthy microbiota can also benefit the immune system. Severe infection of the respiratory epithelium can lead to acute respiratory distress syndrome (ARDS), characterised by excessive and damaging host inflammation, termed a cytokine storm. This is seen in cases of severe COVID-19. There is evidence from ARDS in other settings that the cytokine storm can be controlled by n-3 fatty acids, possibly through their metabolism to specialised pro-resolving mediators.
DOI : 10.1136/bmjnph-2020-000085
ISSN: 2516-5542
Cilt: 3
Sayı: 1
Sınıflandırma :
24
COVID-19 Testing
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Disease-a-Month
Yayıncı:
Elsevier
Yazar(lar) :
R.B. McFee
Yıl :
2020
COVID-19 Testing
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.disamonth.2020.101059
ISSN: 0011-5029
Sayfa: 101059
Sınıflandırma :
25
COVID-19: endgames
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
The Lancet Infectious Diseases
Yayıncı:
Elsevier
Yıl :
2020
COVID-19: endgames
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/s1473-3099(20)30298-x
ISSN: 1473-3099
Sayı: 5
Cilt: 20
Sayfa: 511
Sınıflandırma :
26
Pharmacogenomics of COVID-19 therapies
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
npj Genomic Medicine
Yazar(lar) :
Takuto Takahashi , Jasmine A. Luzum , Melanie R. Nicol , Pamala A. Jacobson
Yıl :
2020
Pharmacogenomics of COVID-19 therapies Abstract A new global pandemic of coronavirus disease 2019 ( COVID- 19) has resulted in high mortality and morbidity. In conclusion, although direct evidence in COVID- 19 patients is lacking, we identified potential actionable genetic markers in COVID- 19 therapies. Clinical studies in COVID- 19 patients are deemed warranted to assess potential roles of these markers.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Abstract A new global pandemic of coronavirus disease 2019 (COVID-19) has resulted in high mortality and morbidity. Currently numerous drugs are under expedited investigations without well-established safety or efficacy data. Pharmacogenomics may allow individualization of these drugs thereby improving efficacy and safety. In this review, we summarized the pharmacogenomic literature available for COVID-19 drug therapies including hydroxychloroquine, chloroquine, azithromycin, remdesivir, favipiravir, ribavirin, lopinavir/ritonavir, darunavir/cobicistat, interferon beta-1b, tocilizumab, ruxolitinib, baricitinib, and corticosteroids. We searched PubMed, reviewed the Pharmacogenomics Knowledgebase (PharmGKB®) website, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, the U.S. Food and Drug Administration (FDA) pharmacogenomics information in the product labeling, and the FDA pharmacogenomics association table. We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). We also identified other variants, that are associated with adverse effects, most notable in hydroxychloroquine/chloroquine (G6PD; hemolysis), ribavirin (ITPA; hemolysis), and interferon β -1b (IRF6; liver toxicity). We also describe the complexity of the risk for QT prolongation in this setting because of additive effects of combining more than one QT-prolonging drug (i.e., hydroxychloroquine/chloroquine and azithromycin), increased concentrations of the drugs due to genetic variants, along with the risk of also combining therapy with potent inhibitors. In conclusion, although direct evidence in COVID-19 patients is lacking, we identified potential actionable genetic markers in COVID-19 therapies. Clinical studies in COVID-19 patients are deemed warranted to assess potential roles of these markers.
DOI : 10.1038/s41525-020-00143-y
ISSN: 2056-7944
Cilt: 5
Sayı: 1
Sayfa: 1 - 7
Sınıflandırma :
27
COVID-19 in hematological malignancies
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Cancer Research, Statistics, and Treatment
Yazar(lar) :
Bhausaheb Bagal , Pritesh Munot , Lingaraj Nayak
Yıl :
2020
COVID-19 in hematological malignancies
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.4103/CRST.CRST_182_20
Cilt: 3
Sayı: 2
Sayfa: 345 - 345
Sınıflandırma :
28
COVID-19 and our DNA
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
The International Journal of Frontier Sciences
Yazar(lar) :
Muhammad Aslamkhan
Yıl :
2020
COVID-19 and our DNA covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
On December 31st 2019, Chinese Health Authorities in Wuhan city of their Hubei province, diagnosed 29 pneumonia cases of unknown etiology and informed WHO (World Health Organization). The unknown virus resembled SARS (severe acute respiratory syndrome), that occurred in China in November 2002, caused by a novel corona virus spilling over from an animal reservoir and transmitted by respiratory droplets. More than 8000 cases and 774 deaths were caused by SARS and circa US$20 billion coasted for its control.
DOI : 10.37978/tijfs.v4i2.206
Anahtar Kelimeler : covid-19, epidemic, epidemiology, genetic susceptibility, genome, pakistan, rna enveloped viruses, wuhan
Cilt: 4
Sayı: 2
Sayfa: 55 - 58
Sınıflandırma :
Viroloji %100
29
COVID-19: Infection or Autoimmunity
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Immunology
Yazar(lar) :
Timothy Icenogle
Yıl :
2020
COVID-19: Infection or Autoimmunity The clinical and laboratory features of COVID- 19 are reviewed with attention to the immunologic manifestations of the disease. Recent COVID- 19 publications describe a variety of clinical presentations including an asymptomatic state, pneumonia, a hemophagocytic lymphohistiocytosis - 19. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The clinical and laboratory features of COVID-19 are reviewed with attention to the immunologic manifestations of the disease. Recent COVID-19 publications describe a variety of clinical presentations including an asymptomatic state, pneumonia, a hemophagocytic lymphohistiocytosis like syndrome, Multisystem Inflammatory Syndrome in Children (MIS-C) but, also called Pediatric Inflammatory Multisystem Syndrome-Toxic Shock (PIMS-TS), Kawasaki Disease, and myocarditis. A common theme amongst multiple reports suggests an overexuberant autoimmune component of the disease but a common pathophysiology to explain the variations in clinical presentation has been elusive. Review of the basic science of other viral induced autoimmune disorders may give clues as to why immunosuppressive and immunomodulating regimens now appear to have some efficacy in COVID-19. Review of the immunopathology also reveals other therapies that have yet to be explored. There is potential use of T cell depleting therapies and possibly anti-CD20 therapy for COVID-19 and clinical research using these medications is warranted.
DOI : 10.3389/fimmu.2020.02055
Anahtar Kelimeler : COVID-19, autoimmunity, myocarditis, hemophagocytic lymphohistiocytosis, thymoglobulin, rituximab
ISSN: 1664-3224
Cilt: 11
Sınıflandırma :

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler